全球 CD47 抑制剂市场：临床试验见解与市场机会展望（2028）

Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028

出版日期: 2024年09月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

抑制细胞表面蛋白 CD47 已成为一种新型的癌症免疫治疗方法，近年来引起了学术界和工业界的兴趣。癌细胞通常过度表现CD47，触发 "别吃我" 讯号通路，帮助恶性细胞逃避免疫监视。 CD47抑制剂目的是透过抑制这种蛋白质来清除癌细胞，使它们更容易受到免疫系统的攻击，特别是透过增强巨噬细胞的吞噬作用。目前，尚无 CD47 抑制剂已被批准用于治疗，但有候选药物进行 3 期临床试验，这可能会在未来几年内获得批准。

由于多个候选药物处于不同的开发阶段，CD47 抑制剂的研究和开发领域迅速发展。现在Gilead下的Forty Seven开发的Magrolimab，是最先进的CD47 抑制剂之一。血液恶性肿瘤的早期临床试验已显示出有希望的结果，特别是与其他癌症治疗相结合时。此外，实体肿瘤的后期临床试验目前评估Magrolimab与docetaxel、Nivolumab、Pembrolizumab、Azacitidine 和 Venetoclax等传统癌症治疗的结合。

ALX Oncology 的Evorpacept（ALX148）是一种抑制 CD47 的高亲和力 SIRPa 融合蛋白，也是一个重要的候选者。 Evorpacept 目前多种实体癌和血液癌的多项早期临床试验中进行评估，既可以作为单一疗法，也可以与广泛使用的抗癌药物联合使用。此外，后期临床试验进行中，评估 Evorpacept 合併Trastuzumab、Ramucirumab和Paclitaxel治疗 HER2+ 胃癌。其他CD47抑制剂也处于临床研究的早期阶段，包括TQB 2928（正大天晴药业）、MP 0621（Molecular Partners）、IMC-002（ImmuneOncia Therapeutics）和CC 90002（Celgene）。

中国和美国公司目前占据市场主导地位，但韩国、澳洲、加拿大和日本也日益进入该市场。透过临床研究，Shaperon、InnovationBio、Bitterroot Bio 和 ImmuneOncia Therapeutics 等公司 CD47 抑制剂方面取得长足进展。市场竞争激烈，多家企业争夺市场占有率。因此，基于安全性、功效和可能的组合策略的差异化对于商业成功非常重要。

本报告检视了全球 CD47 抑制剂市场，并概述了市场、药物趋势、临床试验趋势、区域趋势以及进入市场的公司的竞争格局。

Global & Regional Market Opportunity Outlook
Insight On More Than 100 CD47 Inhibitor Drugs In Clinical Trials
Global CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
Orphan, Fast Track, Breakthrough Therapy Designation Insight
Key Drugs Initiation & Completion Year
CD47 Clinical Application & Development Outlook By Indication
CD47 Inhibitor Drugs Clinical Developments & Trends By Country
Global CD47 Inhibitor Drug Market Dynamics

Inhibition of the cell surface protein CD47 has emerged as a novel cancer immunotherapy approach that has piqued the interest of both academia and industry in the recent years. Cancer cells often overexpress CD47, which triggers the "don't eat me" signal pathway, thereby helping malignant cells to escape immune surveillance. CD47 inhibitors seek to uncover cancer cells by inhibiting this protein, leaving them open to immune system attack, specifically through increased macrophage phagocytosis. Although no CD47 inhibitor is currently approved for therapeutic usage, the availability of candidates in phase 3 trials suggests that one may be approved in the coming years.

With multiple candidates at varying stages of development, the field of CD47 inhibitor research and development is rapidly evolving. Developed by Forty Seven, which is now a part of Gilead, magrolimab is among the most advanced CD47 inhibitors. In early stage clinical trials for hematological tumors, it has demonstrated encouraging outcomes, especially when combined with other cancer treatments. Furthermore, late stage clinical trials evaluating Magrolimab in solid cancer alongside conventional cancer treatments such as docetaxel, Nivolumab, Pembrolizumab, Azacitidine, and Venetoclax are now under progress.

Another significant candidate is Evorpacept (ALX148) from ALX Oncology, a high affinity SIRPa fusion protein that inhibits CD47. Currently, evorpacept is being assessed as a monotherapy and in combination with widely used anticancer drugs in a number of early phase clinical trials for a variety of solid and hematological tumors. Furthermore, a late-phase trial evaluating Evorpacept in combination with Trastuzumab, Ramucirumab, and Paclitaxel for the treatment of HER2+ gastric cancer is also under progress. A number of other CD47 inhibitors, including as TQB 2928 (Chia Tai Tianqing Pharmaceutical), MP 0621 (Molecular Partners), IMC-002 (ImmuneOncia Therapeutics), and CC 90002 (Celgene), are in the early phases of clinical research.

The emphasis on combination therapies is undoubtedly one of the key trends in clinical development. Combining CD47 inhibitors with other immunotherapies, targeted treatments, and chemotherapy is being studied in an effort to overcome resistance mechanisms and provide synergistic benefits.

Anticipated growth in the global market for CD47 inhibitors is attributed to the rising cancer incidence and increased use of immunotherapies in the upcoming years. The potential of CD47 inhibitors has been acknowledged by a number of prominent pharmaceutical companies, which has resulted in notable partnerships and acquisitions. The commercial interest in this field is demonstrated by Gilead Science's US$ 4.9 billion acquisition of Forty Seven in 2020 and Pfizer's US$ 2.26 billion acquisition of Trillium Therapeutics in 2021.

Although Chinese and American companies presently dominate the market, there is increasing participation from South Korea, Australia, Canada, and Japan. Through clinical research, companies such as Shaperon, InnobationBio, Bitterroot Bio, and ImmuneOncia Therapeutics are making strides with their CD47 inhibitors. The market is becoming increasingly competitive, with several firms striving for market share. Therefore, for commercial success, differentiation based on safety profile, efficacy, and possible combination strategies will be essential.

The market for CD47 inhibitors has both opportunities and challenges. Strong commercial interest and encouraging clinical evidence point to substantial development potential. However, there are challenges to address, such managing toxicity profiles, coming up with the best combination plans, and demonstrating distinct therapeutic advantages over current treatments. As the field develops, biomarker development for response prediction and patient selection will probably become more crucial for clinical development as well as marketing tactics.

In conclusion, the market for CD47 inhibitors globally is an active rapidly expanding area of cancer immunotherapy. In the years to come, CD47 inhibitors could have a big impact on cancer therapy paradigms because there are several candidates in clinical development and a lot of commercial interest.

1. CD 47 As Novel Cancer Immunotherapy Target

2. Global CD47 Inhibitors Drug Clinical Pipeline Overview

2.1 By Country
2.2 By Company
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase
2.6 By Priority Status

3. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase II/III
3.7 Phase III

4. Global CD47 Inhibitor Drug Market Opportunity Outlook

4.1 Current Market Overview
4.2 Future Outlook & Opportunities

5. CD47 Clinical Application & Development Outlook by Indication

5.1 Solid Cancers
- 5.1.1 Breast Cancer
- 5.1.2 Colorectal Cancer
- 5.1.3 Lung Cancer
- 5.1.4 Urogenital Cancer
- 5.1.5 Gastrointestinal Cancer
5.2 Hematological Malignancies
- 5.2.1 Lymphoma
- 5.2.2 Leukemia
- 5.2.3 Multiple Myeloma
- 5.2.4 Myelodysplastic Syndrome
5.3 Microbial Infections

6. CD47 Inhibitor Drugs Clinical Developments & Trends By Country

6.1 China
6.2 US
6.3 South Korea
6.4 Australia
6.5 Canada

7. Global CD47 Inhibitors Market Dynamics

7.1 Favorable Parameters
7.2 Market Restraints

8. Competitive Landscape

8.1 Adagene
8.2 ALX Oncology
8.3 ImmuneOncia Therapeutics
8.4 ImmuneOnco Biopharma
8.5 Light Chain Bioscience
8.6 Phanes Therapeutics
8.7 Virtuoso Therapeutics

简介目录图表

List of Figures

Figure 2-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2022 Till 2028
Figure 2-2: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2022 Till 2028
Figure 2-3: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2022 Till 2028
Figure 2-4: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Patient Segment, 2022 Till 2028
Figure 2-5: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2022 Till 2028
Figure 2-6: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2022 Till 2028
Figure 5-1: NI-1801 Phase I Study (NCT05403554) - Initiation & Completion Year
Figure 5-2: ALX148 Phase I Study (NCT05868226) - Initiation & Completion Year
Figure 5-3: Ligufalimab Phase II Study (NCT05382442) - Initiation & Completion Year
Figure 5-4: PT217 Phase I/II Study (NCT05652686) - Initiation & Completion Year
Figure 5-5: HMPL-A83 Phase I Study (NCT05429008) - Initiation & Completion Year
Figure 5-6: ALX148 Phase I Study (NCT05524545) - Initiation & Completion Year
Figure 5-7: PT217 Phase I/II Study (NCT05652686) - Initiation & Completion Year
Figure 5-8: AK117 Phase II Study (NCT05382442) - Initiation & Completion Year
Figure 5-9: AK117 Phase I/II Study (NCT05214482) - Initiation & Completion Year
Figure 5-10: AK117 Phase II Study (NCT05960955) - Initiation & Completion Year
Figure 5-11: Evorpacept Phase II/III Study (NCT05002127) - Initiation & Completion Year
Figure 5-12: PT886 Phase I/II Study (NCT05482893) - Initiation & Completion Year
Figure 5-13: CC-96673 Phase I Study (NCT04860466) - Initiation & Completion Year
Figure 5-14: HCB101 Phase I Study (NCT05892718) - Initiation & Completion Year
Figure 5-15: Evorpacept Phase I/II Study (NCT05025800) - Initiation & Completion Year
Figure 5-16: AK117 Phase I/II Study (NCT04980885) - Initiation & Completion Year
Figure 5-17: AK117 Phase I/II Study (NCT06387420) - Initiation & Completion Year
Figure 5-18: TQB 2928 Phase I Study (NCT06008405) - Initiation & Completion Year
Figure 5-19: SL-172154 Phase I Study (NCT05275439) - Initiation & Completion Year
Figure 5-20: SL-172154 Phase Ib Study (NCT05275439) - Initiation & Completion Year
Figure 5-21: Ligufalimab Phase Ib Study (NCT04900350) - Initiation & Completion Year
Figure 6-1: South Korea - Prominent CD47 Inhibitor Developers
Figure 7-1: Global CD47 Inhibitors Market - Drivers & Opportunities
Figure 7-2: Global CD47 Inhibitors Market - Challenges & Restraints